MELİH ATAHAN GÜVEN, İBRAHİM EGEMEN ERTAŞ
Gynecology Obstetrics & Reproductive Medicine - 2005;11(3):180-182
OBJECTIVE: The aim was to determine the therapeutic efficacies of two different gonadotropin-releasing hormone analogs in patients with symptomatic uterine leiomyoma. STUDY DESIGN: Twenty women with symptomatic uterine leiomyomas awaiting elective surgical treatment (either myomectomy or hysterectomy) were randomly divided into two groups. Nine patients received gosereline acetate 3.6 mg (Zoladex®, Astra Zeneca) subcutaneously and 11 patients triptoreline acetate 3.75 mg (Decapeptyl®, Ipsen Pharmaceuticals) intramusculary every four weeks for a period of 12 weeks beginning on one of the first three days of the menstrual cycle. Changes in myoma volume were ascertained by magnetic resonans imaging (n:18) or computed tomography (n:2). Hormone profiles were obtained for both groups before and after completion of therapy. Surgical treatment was carried out three to five weeks after the last administration of the gonadotropin-releasing hormone analog. RESULTS: Leiomyoma volume decreased in the triptoreline acetate group from 121±221 mm3 to 41±40 mm3 (P=0.003) and in the gosereline acetate group from 239±352 mm3 to 98±146 mm3 (p=0.008) after the therapy. The post-therapy FSH level was significantly lower in the triptoreline acetate group (5.6±1.9 versus 9.2±4.2, p=0.007). CONCLUSION: GnRH-analogs are an effective therapeutic tool for reduction of myoma size. Two pre-operative GnRH-analogs shows similar results, in terms of uterine shrinkage and basal hormon profiles.
